Group items tagged

The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to serve as the Research Center (RC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases. The purpose of the LungMAP RCs will be to generate the molecular profiling data of the developing human lung. Applicants are not required to have been funded in Phase 1 (RFA-HL-14-008) in order to submit applications for Phase 2.

The overall objective of the LungMAP is to better understand human lung development by building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 1 of the LungMAP has generated foundational data from developing mouse and human lungs, created a web portal for public data sharing, and established a repository of human lung tissues. Phase 2 of the LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases.

Age is the number one risk factor for diagnosis of many age-related lung diseases, including COPD and pulmonary fibrosis. Despite this, little is known regarding the interactions that likely occur between the molecular and cellular mechanisms of disease and the changes in molecules and cells that can be attributed to normal aging. In fact, very little is known about the normal aging process in the lung at the cellular and molecular level. In 2015, the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Aging (NIA) co-sponsored a workshop that identified a major knowledge gap in the understanding of normal lung aging in humans, as well as the need to develop a map of molecular changes that occur during normal aging in the lung that can serve as a reference for studies of age-related lung diseases.

Through the program, grants of $50,000 per year for up to two years will be awarded to junior investigators on the path to independence for research on the mechanisms and biology of interstitial lung disease.The Dalsemer Research Grant is for $50,000 per year, for up to two years. Grants are subjected to annual review and may be granted for two years. The second year of support is based on demonstrating satisfactory progress, as well as, the availability of funding from the Lung Association. Applicants should be on-track to pursue a career in lung heath research with a mentor who has a demonstrated history of lung disease research and mentorship.

The overall objective of the LungMAP is to better understand human lung development by building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 1 of the LungMAP has generated foundational data from developing mouse and human lungs, created a web portal for public data sharing, and established a repository of human lung tissues. Phase 2 of the LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung.

The American Association for Cancer Research-Johnson & Johnson Lung Cancer Innovation Science Grants program is a joint effort to address the need for promoting and supporting collaborative cancer research in areas that include digital therapeutics and smoking cessation, as well as biomarkers/behavioral phenotyping that bolster  understanding of how lung cancer can be successfully intercepted.  To that end, a grant of $1 million over three years will be awarded to a multi-institutional team in support of a new idea and/or innovative approach that has direct application and relevance to lung cancer prevention and interception. The proposed research should be translational in nature and include a clinical component with an endpoint relevant to improving the detection or treatment of lung cancer.

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to develop novel in vivo imaging technologies using molecular probes that target pathways or cells involved in the pathobiology of pulmonary diseases. The long-term goal of this program is to develop novel molecular imaging entities and approaches that facilitate early detection and diagnosis of lung disease, enable noninvasive monitoring of lung disease progression and prognosis, and accelerate progress of cell-specific drug delivery and therapies.The previous FOA (RFA-HL-12-036 - Phase 1) supported projects to develop and validate innovative novel imaging agents and approaches that included target selection, probe development and production, and initial characterization of the probe. Phase 2 of this initiative will support studies that advance translation of identified probes and associated imaging approaches from animal models into applicability for human lung diseases. Phase 2 studies must include work performed in vivo using appropriate animal models of lung diseaseand studies using human tissues and/or cells. Applications proposing Investigational New Drug (IND)-enabling studies of novel probes and imaging approaches are encouraged. Applicants are not required to have been funded in Phase 1 (RFA-HL-12-036) in order to submit applications for Phase 2.

The Idea Development Award promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths from lung cancer. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. New Investigators: The FY16 Idea Development Award mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment, or equivalent). The New Investigator category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in lung cancer research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PI's expertise to best address the research question. All applicants for the New Investigator category must meet specific eligibility criteria as described in Section I.D., Eligibility Information. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

This Funding Opportunity Announcement (FOA) invites applications for basic research to elucidate the impact of microenvironment, which includes cellular components of the niche, extracellular matrix, and soluble factors, on lung progenitor cell phenotype and function during development, homeostasis, repair and regeneration. Multi-disciplinary teams with complementary expertise are encouraged to propose innovative, hypothesis-based studies to catalyze this understudied area critical to advancing lung stem cell biology. This FOA will also support the development of novel 3-dimensional, multi-component models to interrogate lung stem cell niches. 

This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.

This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.

This Funding Opportunity Announcement (FOA) invites applications for basic research to elucidate the impact of microenvironment, which includes cellular components of the niche, extracellular matrix, and soluble factors, on lung progenitor cell phenotype and function during development, homeostasis, repair and regeneration. Multi-disciplinary teams with complementary expertise are encouraged to propose innovative, hypothesis-based studies to catalyze this understudied area critical to advancing lung stem cell biology. This FOA will also support the development of novel 3-dimensional, multi-component models to interrogate lung stem cell niches.

To be eligible, applicants should be on track to a career in lung health research and have a mentor with a demonstrated history of lung disease research and mentorship. At the time of application, candidates must be a citizen of the United States or a foreign national holding one of the following visa immigration statuses: permanent resident (Green Card); exchange visitor (J-1); temporary worker in a specialty occupation (H-1B); Canadian or Mexican citizen engaged in professional activities (TN); Australians in Specialty Occupation (E-3); or temporary worker with extraordinary abilities in the sciences (O-1). At the time of application and throughout the duration of the award, award recipients must be employed by a U.S. institution.

The Investigator-Initiated Translational Research Award (IITRA) supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician's firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following: * Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts. * Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission. * Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

The Lung Cancer Research Foundation's grant program provides funding for innovative research focused on the prevention, diagnosis, treatment and cure of lung cancer. The Foundation encourages applications for projects investigating a wide variety of research topics.

The purpose of this Funding Opportunity Announcement (FOA) is to invite grant applications to establish new and innovative epidemiology cohort studies that will prospectively follow at least 2,000 participants and are designed to study a wide range of research hypotheses related to heart, lung, blood, and/or sleep phenotypes. Through this FOA, the National Heart, Lung, and Blood Institute (NHLBI) will support activities required to establish a new cohort, including identification and recruitment of cohort participants, detailed baseline data collection on all participants, biospecimen collection and storage, study infrastructure, and data quality control and analysis.

The purpose of this funding opportunity announcement (FOA) is to support functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial ecology, biotechnology, and bioinformatics.

This Funding Opportunity Announcement (FOA) seeks grant applications for a Research Coordinating Center (RCC) to support associated "Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV (HLB SIMPLe)" UG3/UH3 phased cooperative agreements that propose to optimally and sustainably address late-stage implementation research questions to address the delivery of proven-effective prevention and treatment interventions for heart, lung, blood, and sleep (HLBS) comorbid diseases and disorders in people living with HIV (PLHIV) in World Bank designated low- and middle-income countries (LMICs) and Small Island Developing States (SIDS). For the purposes of this FOA, late-stage implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions in routine clinical, public health, and community-based settings and maximize the positive impact on population health. The RCC will coordinate the collaborative efforts of the global alliance of funded UG3/UH3 phased cooperative agreements conducting late-stage implementation research within the following geographical regions: East Asia and the Pacific, Europe and Central Asia, Latin America and the Caribbean, Middle East and North Africa, South Asia, and Sub-Saharan Africa. The HLB SIMPLe RCC will coordinate activities including in-person and virtual Network Steering Committee meetings, subcommittee meetings, and working groups; promote collaboration and communication among investigators and the broader research community; coordinate network outreach activities; coordinate joint research and capacity building efforts conducted across the HLB SIMPLe alliance; and organize, implement, and manage a global implementation research data safety and monitoring board (DSMB). Also listed under UG3/UH3

Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged.Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.Key elements of this award are as follows.

Target poorly membrane-permeable peptides Molecular weight: Approx. 500-2000 Technology requirements The Client seeks either one of the following types of technologies: (1) A formulation / DDS technology to deliver poorly membrane-permeable peptides into target cells Target sites / diseases: Not specified                        * Excludes technologies that are applicable only to cancer cells Routes of administration: Oral, intravenous, subcutaneous and intramuscular injections (delivered through blood vessels into target cells), transnasal (delivered from olfactory bulbs into brain tissues), transpulmonary (delivered into / retained in lung cells, for lung diseases), etc. (2) A formulation / DDS technology to enhance gastrointestinal absorption of poorly membrane-permeable peptides with both of para- and trans-cellular routes.